Article Details
Retrieved on: 2022-05-05 15:29:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Enhertu's fast momentum has already put pressure on Roche, which has multiple HER2-targeting medicines, as well as SeaGen and Macrogenics. Notably, ...
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here